Medad Technology's ultrasonic delivery system revolutionizes HealthTech with scalable applications in consumer and pharmaceutical markets

The core system has 3 key product applications that provide cutting-edge solutions to tackle tobacco dependance and improve drug delivery, with design scalability to meet diverse market needs.

Consumer HealthTech
Ultrasonic E-cigarette

Our ultrasonic delivery system can be used to deliver nicotine as an ultrasonic e-cigarette. Why use ultrasound for nicotine delivery? The burning or heating of tobacco and nicotine at high temperatures leads to the formation of toxic chemicals that cause diseases. Using ultrasound removes the need to heat nicotine e-liquid, eliminating toxic chemicals and reducing potential harm. Instead of a vapour, the e-liquid is aerosolized into a cool, clean mist.

Our 'misting' technology provides an opportunity for the introduction of a novel category of reduced-risk, smoke-free products that can meet regulatory requirements and further support Tobacco Harm Reduction initiatives. It also has the potential to address nicotine abuse liability concerns. E-cigarettes are less efficient at delivering nicotine which can lead to overuse, or paradoxically, drive users back to combustible cigarettes. Our proprietary algorithm controls particle size, resulting in a narrow particle distribution that optimizes aerosol delivery to the alveoli. This has the potential to improve product satisfaction with reduced nicotine concentrations.

The escalating youth vaping epidemic, driven by appealing flavours and accessibility, along with a surge in illicit and counterfeit products, presents a significant challenge and raises safety concerns. Our technology addresses these issues with an in-app age verification process which requires an ID check for device activation. To safeguard against counterfeit products, we use our proprietary pod authentication system with an OTP chip.

Pharmaceutical HealthTech
Nicotine Replacement Therapy

Existing Nicotine Replacement Therapies (NRTs) are safe but fail to deliver nicotine rapidly or satisfy the habitual, sensorial cravings, reducing its effectiveness as a smoking cessation aid. As a result, NRTs are losing popularity, with many smokers turning to e-cigarettes as a solution for quitting smoking. E-cigarettes are proving to be effective but raise safety concerns, especially with the rise of unregulated products entering the market. Although toxic emissions are significantly reduced, thermal degradation of the e-liquid does occur, and further additives found in unlicensed products could increase the risk of potential harm.

Smokers need access to an improved NRT that offers the same safety profile but is as effective as e-cigarettes. With our ultrasonic nicotine delivery system (UNDS), we deliver nicotine more efficiently than traditional NRTs and e-cigarettes, whilst delivering on sensorial cues through inhalation, improving quitting success rates.

Our UNDS comes with a digital companion app that is available on IOS and Android for monitoring and behavourial support. It can track consumption data such as number of inhalations and provide push notifications to help users manage their habit. Research indicates that the efficacy of tobacco dependence treatments is enhanced when smoking cessation aids are coupled with behavioral therapy. We have partnered with one of the world's leading medical establishments, Mayo Clinic, and their Foundation for Medical Education & Research, to explore the development of new treatments and innovative strategies for treating tobacco users, leveraging digital strategies and interventions.

Pharmaceutical HealthTech
Smart Nebulizer

High quality healthcare for complex conditions is intricate and highly personal. However, existing treatments are often impersonal, generic and in the less effective form of a pill. Oral medications and existing inhaler treatments are not fast acting as the medication needs to be absorbed into the blood stream before taking effect, has limited dosing options and side effects.

Existing inhaler technologies target the 1st, 2nd and 3rd generation airways in the lungs which is effective for the treatment of respiratory diseases. Targeting the 4th generation airways leads directly into the alveolar spaces which can provide efficacy outside of the respiratory tract through systemic exposure. This requires a particle size below 1µm.

With our technology and algorithm, we can control the particle size and distribution to directly target the 4th generation airways, for extra-pulmonary efficacy. Delivering through the alveolar in the lungs directly into oxygenated blood negates the effects of metabolism on drug delivery, improving efficacy and reducing unwanted side effects. Systemic delivery also provides an opportunity for treatment of disease outside of the respiratory tract.